Introduction {#s02}
============

Ion channelopathies {#s03}
-------------------

Ion channels are ubiquitously expressed throughout the body and perform key membrane transport processes crucial to normal physiological function. Pathogenic alterations to ion channel activity can disrupt homeostatic and physiological functions leading to disorders such as hemiplegic migraines, epilepsy, or cardiac arrhythmias, collectively referred to as \"channelopathies" ([@bib11]; [@bib76]; [@bib105]). Channelopathies are rare monogenetic disorders stemming from inherited or de novo mutations in genes encoding the functional components of ion channels. Advancements in whole exome sequencing (WES) have contributed to a growing list of diagnosable monogenetic channelopathies ([@bib76]), yet the molecular basis for these genetic mutations and how they produce clinical phenotypes are not fully established in many cases. Current understandings of channelopathies are limited by several factors, such as deficiencies in (a) the direct evidence for causality due to a very limited number of patients and lack of genetic pedigree analysis, (b) the functional data for the classification of mutant channel properties, and (c) the tissue loci and nature of aberrant excitability linked to abnormal patient phenotypes. This review will focus on one channelopathy involving the large conductance Ca^2+^ and voltage-activated K^+^ (BK, K~Ca~1.1) channel, encoded by *KCNMA1*. The hallmark clinical presentation of *KCNMA1*-linked channelopathy is neurological dysfunction, including seizures, movement disorders, developmental delay, and intellectual disability.

BK channel structure {#s04}
--------------------

The *KCNMA1* gene, located on human chromosome 10q22.3, produces the pore-forming α-subunit of the BK channel ([@bib30]; [@bib122]; [@bib98]). BK channels, named for their "Big K^+^" conductance (\>100 pS), are members of the voltage-gated K^+^ channel family and mediate K^+^ efflux from excitable and non-excitable cells ([@bib82]; [@bib117]). BK channels assemble as homotetramers of the *KCNMA1* gene product. Each α-subunit consists of seven transmembrane domains (S0--S6), and a large intracellular C-terminus ([Fig. 1](#fig1){ref-type="fig"}). The extracellular N-terminus and presence of the S0 transmembrane segment differs between BK and other voltage-gated K^+^ channels and confers interactions with accessory proteins (β and γ subunits; [@bib175]; [@bib111]; [@bib192], [@bib193]). The S1--S4 segments contain positively charged residues and constitute the voltage sensing domain, while the S5--S6 segments form the pore domain, which houses the highly K^+^-selective conduction pathway ([@bib101]; [@bib154]; [@bib61]; [@bib60]; [@bib194]). The intracellular C-terminus of the BK channel encompasses the gating ring, a structure comprised of two regulators of K^+^ conductance (RCK) domains. RCK1 and RCK2 each contain two distinct high-affinity Ca^2+^ binding sites, mediating the allosteric gating of BK channels ([@bib191]; [@bib176]; [@bib85]; [@bib198], [@bib199]; [@bib202]). The human BK channel structure was determined in 2010 ([@bib198]), providing a basis for understanding the location of specific residues, such as mutations, with respect to functional domains.

![**Human *KCNMA1* mutations.** Schematic of the *KCNMA1* gene product, the α-subunit of the BK channel (GenBank accession no. [NM_002247.3](NM_002247.3)). The voltage-sensitive pore-forming region of the BK channel is comprised of transmembrane domains S0--S6, while the intracellular gating ring contains the two Ca^2+^ binding sites in the RCK1 and RCK2 domains. Red indicates GOF mutations (*n* = 2), blue indicates LOF or putative LOF mutations (*n* = 11), and black indicates putative benign mutations (*n* = 3) or VUS (*n* = 1). \*C413Y/N499fs is a double mutation harbored by a single patient. Numbers to the right or left of each mutation indicate the total number of patients carrying each mutation reported in published studies. N995S, N999S, and N1053S are the same amino acid substitution, but are reported in the literature using three different reference sequencing number schemes.](JGP_201912457_Fig1){#fig1}

Voltage and calcium regulation of BK channel activity {#s05}
-----------------------------------------------------

Multiple activation mechanisms are involved in opening the channels in vivo ([@bib66]). Under physiological conditions in excitable cells, the BK channel activation requires both membrane depolarization and an increase in intracellular Ca^2+^ to micromolar levels for activation ([@bib194]). These high concentrations of Ca^2+^ are attained in local microdomains through tight functional coupling with voltage-gated Ca^2+^ channels or channels that release Ca^2+^ from intracellular stores ([@bib37]). Different tissues exhibit BK currents of varying voltage and Ca^2+^-dependent activation properties, underlying the complex roles for BK channels in regulating excitability. This cell and tissue-specific regulation is achieved via extensive alternative splicing of *KCNMA1* transcripts, assembly with modulatory β- and γ-regulatory subunits, and a variety of post-translational modifications ([@bib79]; [@bib83]; [@bib45]). These mechanisms work together to tailor the voltage and Ca^2+^ dependence of channel activation, as well as the kinetics of activation and deactivation gating, for the cell-specific function of BK channels in excitability or K^+^ transport.

Tissue distribution and links to human pathophysiology {#s06}
------------------------------------------------------

In humans, BK channels are widely expressed in the body including nervous, muscular, skeletal, endocrine, cardiovascular, digestive, urinary, and reproductive systems ([Fig. 2](#fig2){ref-type="fig"}; [@bib123]; [@bib3]; [@bib4]; [@bib98]; [@bib59]; [@bib22]; [@bib35]; [@bib21]; [@bib83]; [@bib45]). Prior to the identification of *KCNMA1*-linked channelopathy patients, changes in BK channel expression or activity had been implicated in human studies of erectile dysfunction, overactive bladder, hypertension, and premature uterine contraction during pregnancy ([@bib17], [@bib18]; [@bib104]; [@bib164]; [@bib49]; [@bib196]; [@bib88]). Moreover, several nonsynonymous single nucleotide polymorphisms (SNPs) in *KCNMA1* and genes encoding BK-specific auxiliary β subunits (*KCNMB1-4*) were also linked to human disorders or disease risk, including autism, hypertension and cardiovascular function, and asthma ([@bib44]; [@bib143]; [@bib84]; [@bib52]). Despite these studies implicating BK channel function in several pathological conditions, genetic linkage and analysis of human tissues have revealed only a limited picture of what is known about BK channel roles in vivo. Extensive investigations in animal models, which are more accessible to the interrogation of specific cell types and tissues, have provided a more complete assessment of the various roles for BK channels in physiology and pathophysiology. Although neurological and muscle phenotypes are well represented, BK channel function in rodents is more broadly required for a panoply of organ functions that parallels their wide expression across tissues ([Fig. 3](#fig3){ref-type="fig"}). Taken together, these animal studies detail a greater potential for wide-ranging pathophysiological dysfunction in patients carrying mutations in *KCNMA1*.

![**BK channel expression in human tissues and prominent phenotypes reported in patients with *KCNMA1*-linked channelopathy.** Major tissues or systems expressing BK channels are depicted in black (high relative expression), gray (medium), and light gray (low). Organs demonstrating high levels of BK channel expression include the CNS (olfactory system, neocortex, basal ganglia, hippocampus, thalamus, habenula and its tract to the interpeduncular nucleus in the midbrain, cerebellum, vestibular nuclei in the hindbrain, and spinal cord), gastrointestinal tract (stomach, small intestine, and colon), and reproductive organs (corpus cavernosum, prostate, testes, ovaries, and uterus). Organs demonstrating medium BK channel expression include salivary glands, neuroendocrine glands (thyroid, parathyroid, adrenal), heart, urinary bladder, liver and gallbladder, kidneys, and spleen/immune system. Organs demonstrating low levels of BK channel include lungs, lymph nodes, vasculature, skeletal muscle, and bone. Data on expression levels were derived from the Human Protein Atlas v18.1 (<https://www.proteinatlas.org>; [@bib170]), the NCBI Gene Database (<https://www.ncbi.nlm.nih.gov>), and published reports ([@bib30]; [@bib98]; [@bib12]).](JGP_201912457_Fig2){#fig2}

![**BK channel dysfunction by organ and functional system in rodent models.** BK channel knockout mice (*KCNMA1^−/−^*) show a wider range of pathophysiology compared with human *KCNMA1* patients with LOF mutations. Such findings are consistent with the extensive distribution of BK channels across tissues. Key organ and functional systems disrupted by BK channel dysfunction in mouse models are indicated. BK channel activity was required for several aspects of neurological operations in rodent models, such as regulation of neuronal excitability ([@bib73]; [@bib34]; [@bib13]; [@bib146]; [@bib145]), ​locomotor function ([@bib106]; [@bib136]; [@bib16]), circadian rhythm ([@bib107]; [@bib75]; [@bib110]; [@bib185]; [@bib187]), learning and memory ([@bib169]), vision ([@bib57]; [@bib48]; [@bib160]), hearing and vestibular reflexes ([@bib130]; [@bib94]; [@bib134]; [@bib129]; [@bib116]), and neurovascular coupling ([@bib39]; [@bib41]). In addition to neurological roles, rodent models further revealed that BK channels are required for regulation of cardiovascular function ([@bib137]; [@bib70]; [@bib80]; [@bib113]), airway control ([@bib139]; [@bib43]; [@bib95])​, urination ([@bib106]; [@bib163]; [@bib14]; [@bib152])​, glucose homeostasis ([@bib67]; [@bib29])​, renal K^+^ homeostasis ([@bib92]; [@bib132]), reproductive function ([@bib183], [@bib184]; [@bib88]), ethanol intoxication ([@bib96]; [@bib125]), gastrointestinal function ([@bib138]; [@bib150]), body weight ([@bib51]), pain ([@bib54]), immunity ([@bib32]), bone remodeling ([@bib141]; [@bib55]), and salivary secretion ([@bib97]; [@bib157]).](JGP_201912457_Fig3){#fig3}

*KCNMA1* patient mutations {#s07}
--------------------------

16 *KCNMA1* mutations in 37 symptomatic patients have been reported in the literature to date ([Fig. 1](#fig1){ref-type="fig"}). Functional classifications into GOF and LOF effects on channel properties have been based on expression of BK channel complementary DNAs harboring the patient mutations in nonexcitable heterologous cell lines ([Table 1](#tbl1){ref-type="table"} and Supplemental text). From these studies, two mutations have been shown to confer GOF properties to BK channels: D434G and N995S (also referred to as N999S or N1053S; [@bib28]; [@bib203]; [@bib87]; [@bib126]). 10 mutations have been classified as LOF (S351Y, G354S, G356R, G375R, C413Y/N449fs, I663V, P805L, and D984N; [@bib15]; [@bib89]) or putative LOF (premature truncation mutations: Y676Lfs\*7 and Arg458Ter; [@bib158]; [@bib197]). The remaining mutations have not yet been conclusively defined with respect to channel properties (variant of unknown significance, VUS; E884K; [@bib203]) or have not been demonstrated to produce changes in channel function (K518N, E656A, and N1159S; [@bib87]).

###### *KCNMA1* mutation effects on BK channel function

  **Mutation**                           **BK current properties**   **Mechanism**
  -------------------------------------- --------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  D434G                                  Increased current           G-V shift to hyperpolarized potentials, increased open probability, faster activation, slower deactivation, increased Ca^2+^ sensitivity ([@bib28]; [@bib26]; [@bib177]; [@bib195]; [@bib126])
  N995/999/1053S                         Increased current           G-V shift to hyperpolarized potentials, increased open probability, faster activation, slower deactivation, Ca^2+^-independent mechanism ([@bib87]; [@bib126])
  S351Y, G356R, G375R, N449fs\*, I663V   No current                  Not determined ([@bib89])
  C413Y, P805L                           Reduced current             G-V shift to depolarized potentials, decreased expression (P805L; [@bib89])
  D984N                                  Reduced current             Not determined ([@bib89])
  G354S                                  Reduced current             Slower activation ([@bib15])
  R458Ter, Y676Lfs\*7                    Not determined              Putative truncations ([@bib158]; [@bib197])
  K518N, E656A, N1195S                   No current difference       [@bib87]
  E884K                                  Not determined              [@bib203]

Dark gray, GOF mutations; light gray, LOF mutations; no shading, VUS. Full descriptions of experimental investigations for mutant channel properties are contained in Supplemental text. The N995S/N999S/N1053S mutation is reported in the literature using three different reference sequence numbering schemes but constitutes the same residue substitution (Figure 1). In this review, this mutation will be referred to by the numbering scheme in the original publication for the data being discussed.

The majority of the mutations are de novo variants, and patients are heterozygous ([Fig. 1](#fig1){ref-type="fig"}). Since BK channels are comprised of tetramers of the *KCNMA1* gene product, this presents the potential for mitigation of mutant effects by coassembly with WT subunits in heterozygous patients. However, it is not yet known whether tetramers are actually formed between WT and mutant subunits in patients with one normal and one mutant allele, or how the interaction between these subunits would affect BK channel properties. It is also not well studied how the native regulatory processes that set channel function in vivo would combine with the mutation to affect channel properties. It is also possible that some previously established GOF or LOF classifications could change under different experimental conditions than those initially tested. *KCNMA1* patient mutations that have been characterized in at least one standard condition are presented in [Table 1](#tbl1){ref-type="table"} and further described in the Supplemental text.

Neuronal mechanisms of BK channel dysfunction {#s08}
---------------------------------------------

The mechanisms by which *KCNMA1* mutations alter BK channel activity to cause patient symptoms is still an open question. In the central nervous system (CNS), BK channels play an important role in neuronal excitability, passing outward K^+^ current upon membrane depolarization and increased intracellular Ca^2+^ during the action potential, leading to hyperpolarization of the membrane and decreased excitability ([@bib58]). BK current shapes action potential waveforms by mediating the repolarization and afterhyperpolarization (AHP) phases ([@bib144]; [@bib33]; [@bib50]; [@bib93]; [@bib21]). In the majority of neuronal and muscle contexts where the channels are expressed, activation of BK current reduces neuronal firing rates, presynaptic neurotransmitter release, or muscle contraction or tone ([@bib72]; [@bib21]; [@bib166]). In neurons, this decrease in firing is predominantly due to the contribution of BK current to the AHP phase of the action potential ([@bib156]; [@bib21]). In cerebellar Purkinje and dentate gyrus (DG) granule neurons, cell types which have been linked to central neurological phenotypes, the β4 subunit facilitates the suppressive role for BK channels in neuronal firing. β4 subunits slow BK current activation, shifting their activation to the AHP phase ([@bib13]; [@bib189]; [@bib124]; [@bib6]). BK channel activation also reduces excitatory synaptic activity at neuromuscular junctions and in central neurons ([@bib133]; [@bib131]). In smooth muscle cells, BK channels hyperpolarize the membrane potential, which in turn decreases Ca^2+^ influx through voltage-gated Ca^2+^ channels and promotes smooth muscle relaxation ([@bib72]). These studies suggest that LOF in BK channel activity would broadly produce hyperexcitability, such as that resulting in seizure. Consistent with this, at least half of the patients with putative LOF *KCNMA1* mutations have seizures of some type ([Fig. 4](#fig4){ref-type="fig"}).

![**Patient phenotypes for GOF versus LOF *KCNMA1* alleles.** Summary of the main phenotypes exhibited by *KCNMA1*-linked channelopathy patients: seizure, movement disorder, neurodevelopment, and intellectual disability. The denominator is the total number of patients included in each mutation group, and the numerator is the number of patients reported with the particular phenotype. The intersection includes shared symptoms among all patients (*n* = 37) identified with any *KCNMA1* mutation (*n* = 16) reported in this review. Additional subtype descriptors for PNKD, epilepsy, and sensory impairment are annotated. 11/20 of GOF patients had no additional description for their PNKD symptoms in the published reports.](JGP_201912457_Fig4){#fig4}

GOF *KCNMA1* patient mutations are also clearly associated with seizure, raising the possibility that changes in BK channel activity in both directions could alter the balance of excitation and inhibition in the brain. Underlying the potential for bidirectional effects on excitability, BK channels are expressed in both excitatory and inhibitory neurons, and the effects of BK current on firing can vary by neuron type ([@bib21]). Activation of BK current can both decrease and increase neuronal firing rates ([@bib109]), a paradox that can be resolved by understanding the voltage and Ca^2+^ dependence and gating kinetics of the channels in a specific membrane and cellular context. Predicting the effect of BK channel activation on action potential frequency, for example, requires knowledge of the activation, inactivation, and deactivation properties for the BK channels, as well as their subcellular localization and interaction with other ionic currents in that cell ([@bib71]; [@bib93]; [@bib109]; [@bib10]; [@bib21]). The intrinsic gating properties, in turn, are regulated by the subunit composition of the BK channel complex: the α, β, and γ subunits of the BK channel and its associated Ca^2+^ source ([@bib9]; [@bib83]). A pro-excitatory effect of BK channel activation is revealed by BK antagonists that decrease neuronal firing or plateau potentials ([@bib149]; [@bib73]; [@bib174]; [@bib136]; [@bib50]; [@bib5]) or reduce sinoatrial node firing and heart rate ([@bib80]), an opposite effect from the typical result of inhibiting BK channels in most excitable cells. Furthermore, BK channel inhibition has been reported to exert anticonvulsant, rather than epileptogenic, effects in picrotoxin and pentylenetetrazole (PTZ) mouse seizure models ([@bib145]).

The mechanisms underlying the pro-excitatory effects could simply stem from the increased BK current produced by GOF channels hyperpolarizing the membrane of inhibitory neurons. On the other hand, one property correlated with pro-excitatory BK currents is fast activation. More rapid BK current activation directly increases neuronal firing rates by leading to faster repolarization of the action potential ([@bib71]; [@bib93]; [@bib109]; [@bib21]), an effect that could link GOF channels to hyperexcitation and increased firing in excitatory neurons. In addition, rapidly activating BK currents contribute to the fast phase of the AHP, facilitating enhanced Na~v~ channel recovery from inactivation and decreased activation of other K^+^ currents ([@bib174]; [@bib50]; [@bib42]; [@bib178]). Thus, rather than strictly hyperpolarizing membranes due to increased BK current, mutations such as D434G and N995S/N999S/N1053S, which activate more rapidly than WT channels ([@bib28]; [@bib177]; [@bib195]; [@bib87]; [@bib126]), may be capable of directly increasing action potential firing. Thus, the bidirectional and cell-specific effects of BK channels on neuronal excitability suggests that *KCNMA1* mutation-linked dysfunction could disrupt neuronal circuitry and provoke pathological symptoms via multiple potential mechanisms.

KCNMA1-linked channelopathy and the spectrum of patient phenotypes {#s09}
------------------------------------------------------------------

The clinical symptoms of patients with *KCNMA1*-linked channelopathy have not been comprehensively defined but are principally characterized by seizures and movement disorders. Of the 16 *KCNMA1* mutations reported in the literature to date, 4 mutations have been identified in more than one patient ([Fig. 1](#fig1){ref-type="fig"}). Comparison of these cases suggests that patients sharing the same mutation do exhibit similar and/or overlapping neurological and neuromuscular phenotypes, in addition to distinct symptoms. Particularly with the de novo mutations, this provides evidence for the causative nature of the mutations in patient symptoms. The evidence for symptomatic similarities by mutation is summarized in the following.

The D434G *KCNMA1* mutation was identified in 13 members of a large family with symptoms of a coexistent syndrome of generalized epilepsy and paroxysmal dyskinesia ([@bib28]). Within this group, seven patients developed PNKD, one patient developed epilepsy, and five patients developed both symptoms ([@bib28]). These clinical findings were the first to link *KCNMA1* to disease in humans and provided prima facie confirmation of the BK channel's extensive involvement in CNS function.

The N1053S mutation (also called N995S or N999S) has been identified in seven unrelated patients from around the world ([@bib203]; [@bib180]; [@bib87]; [@bib56]) who share similar symptoms with the D434G patients. Of these patients, four developed early onset PNKD, two developed epileptic seizures, and one patient developed both symptoms. In addition, all seven patients were reported to have developmental delays, three patients had intellectual disability, and one patient had other symptoms involving CNS dysfunction, potentially expanding the neurological phenotypes associated with this channelopathy. The symptoms associated with D434G and N1053S mutations constitute the description of phenotype MIM \#609446 ("PKND3") provided by the Online Mendelian Inheritance in Man (OMIM) database (<https://omim.org>).

The Y676Lfs\*7 mutation was identified in two siblings from a consanguineous family ([@bib158]). Both patients were reported to have the same symptoms starting at a young age which included epileptic seizures, severe developmental delay, and nonprogressive cerebellar atrophy ([@bib158]). These two patient cases constitute the description of phenotype MIM \#617643 provided by the OMIM database. While seizure and developmental delay are shared phenotypes with D434G and N995S/N999S/N1053S, cerebellar atrophy without paroxysmal dyskinesia is a distinct phenotype and adds to the variability of neurological symptoms associated with this channelopathy.

The final mutation reported in the literature that is shared by multiple patients is G375R ([@bib89]). This mutation was identified in three unrelated patients who experienced overlapping and heterogenous symptoms. All three patients were reported to have a multiple malformation syndrome characterized by facial dysmorphisms, visceral malformations, development delay, intellectual disability, and axial hypotonia ([@bib89]). Additionally, two of the three patients developed epileptic seizures and one patient had mild cerebral and cerebellar atrophy ([@bib89]). This mutation is associated with the most distinct clinical findings relative to the other three mutations but still demonstrates some phenotypic overlap with the previous mutations regarding neurological and neuromuscular dysfunction.

Of these four *KCNMA1* mutations, D434G exhibited autosomal dominant inheritance and was the only mutation identified in patients from successive generations of a pedigree ([@bib28]). Y676Lfs\*7 demonstrated autosomal recessive inheritance and was identified in a single generation of a pedigree ([@bib158]). These hereditable mutations produced very similar symptoms in affected family members, suggesting a causal role. The remaining two mutations shared by multiple patients were de novo variants (N995S/N999S/N1053S and G375R). In these cases, clinical similarities between patients sharing the same mutations has suggested causality in the absence of comprehensive pedigrees. As a result of the confidence in the *KCNMA1* linkage to patient symptoms, paroxysmal nonkinesigenic dyskinesia-3 with or without generalized epilepsy (PNKD3; MIM \#609446) is now recognized as distinct type of movement disorder linked to at least two mutations in *KCNMA1* (D434G and N995S/N999S/N1053S).

For mutations where only a single patient defines the clinical presentation, causality must still be investigated. Nine additional de novo *KCNMA1* mutations have been reported in the literature where a single patient represents the known symptomatic information. These mutations include: R458Ter\*, G354S, S351Y, G356R, C413Y/N449fs, I6663V, P805L, E884K, and D98N ([@bib203]; [@bib15]; [@bib153]; [@bib89]; [Fig. 1](#fig1){ref-type="fig"}). In these cases, most of the symptoms are similar to those previously described and only a few symptoms do not overlap. For example, seven of the nine patients developed a movement disorder, two developed seizures, all nine were reported to have developmental delay, seven had intellectual disability, and four had abnormal brain imaging indicative of cerebellar atrophy. The new symptoms were mostly related to neurological dysfunction and included autistic like features and areflexia ([@bib89]). These clinical findings suggest semi-distinct phenotypes associated with some of these mutations ([Fig. 4](#fig4){ref-type="fig"}), however the single patient sample size makes it difficult to validate this conclusion.

Lastly, three additional patients with epilepsy were identified to harbor other *KCNMA1* mutations of unknown significance (K518N, E656A, and N1159S). While patch-clamp recordings classified these three variants as benign ([@bib87]), the shared symptom of epileptic seizure with other pathogenic *KCNMA1* mutations may indicate these mutations interfere with BK activity and regulation of neuronal excitability through a yet-to-be-defined mechanism.

Across the *KCNMA1*-linked channelopathy patient population, another important outstanding question is whether patient symptoms and phenotypes can be classified with respect to the functional changes in BK channel activity produced by mutations. Patients with both GOF or LOF *KNCMA1* mutations exhibit overlapping symptoms, especially with respect to seizures and neurodevelopment ([Fig. 4](#fig4){ref-type="fig"}). Thus, combined with the small patient sample size for each mutation, definitive categorization of specific symptoms with increases or decreases in BK channel activity is not yet possible. Moreover, published reports lack detailed clinical description, further limiting the ability to determine if particular symptoms are specific to GOF versus LOF channel mutations. Nevertheless, a few symptoms, primarily movement disorders and muscle dysfunction, appear to be somewhat distinct for GOF versus LOF mutations ([Fig. 4](#fig4){ref-type="fig"}). Below, we summarize the variability of symptoms pertaining to seizure, movement disorder, and neurodevelopment for all patients, while highlighting certain symptoms that may segregate with GOF or LOF mutations.

Movement disorder {#s10}
-----------------

A predominant phenotype of *KCNMA1*-linked channelopathy, regardless of the functional classification of the mutation (GOF, LOF, or VUS), is movement disorder. 24 of the 37 patients were reported to have symptoms related to a movement disorder with variability of the symptomatic presentation among patients. However, there seems to be more apparent segregation by channel functional classification for movement disorder compared with other predominant symptoms like seizures. These symptoms include PNKD (GOF) versus ataxia, axial hypotonia, and tremor (LOF; [Fig. 4](#fig4){ref-type="fig"}).

PNKD was reported in 17 of 20 GOF patients and only 2 of 13 LOF patients ([@bib28]; [@bib203]; [@bib153]; [@bib180]; [@bib197]; [@bib56]). A patient with the VUS E884K mutation was also reported to have paroxysmal dyskinesia ([@bib203]). The paroxysmal dyskinesia symptoms were described as "nonkinesigenic" due to the lack of a movement trigger, in contrast to the more common paroxysmal kinesigenic dyskinesia, which is induced by various movements, and other forms of dyskinesia such as exertion-induced dyskinesia. Although the patients were diagnosed with PNKD, the specific types of movements and body parts involved during PNKD attacks were not stereotypical between patients. For example, the patients with D434G GOF mutation experienced episodes of involuntary mouth movements and hand stiffness during attacks ([@bib28]). Another patient harboring the G354S LOF mutation was reported to have perioral dyskinesia diagnosed at 18 mo ([@bib153]). One patient with the N1053S mutation was diagnosed with PNKD at 7 mo after having paroxysmal dystonic postures ([@bib203]). The three patients with N999S mutations were all diagnosed at different ages with alike paroxysmal drop attacks characterized by behavioral arrest and generalized dystonic posture or stiffening ([@bib56]; A.L. Meredith and S. Keros, personal observations). The frequency and duration of theses movement attacks were variable, ranging from few to many dozens of attacks every day, and lasting a few seconds to minutes. OMIM defines this movement disorder phenotype as "PNKD type 3" or "PNKD3" (MIM \#609446), because *KCNMA1* was the third gene linked to a PNKD phenotype. The other two genes include MR1 located on chromosome 2q35 and PNKD2 on chromosome 2q31, and they correspond to PNKD1 (phenotype MIM \#118800) and PNKD2 (phenotype MIM \#611147), respectively. However, the specific term PKND3 is not systematically used for patients with PNKD and *KCNMA1* mutations in the literature, suggesting existing and new patients expressing similar symptoms should be reevaluated for this diagnosis.

A movement disorder distinct from PNKD, and noted only in LOF patients, was ataxia ([Fig. 4](#fig4){ref-type="fig"}; [@bib15]; [@bib89]), a phenotype also well described in BK channel "knockout" mice harboring a LOF deletion in the *KCNMA1* gene ([@bib106]; [@bib136]; [@bib16]). In patients, the ataxic symptoms included lack of coordination, unbalanced gait, and spasticity of lower extremities. Three of the five ataxic patients also had cerebellar atrophy diagnosed by brain MRI ([@bib15]; [@bib89]), which was another clinical finding distinct for LOF patients. Studies of *KCNMA1^−/−^* mouse models showed reduced basal firing from cerebellar Purkinje neurons and impaired cerebellar signaling and motor coordination, which may offer a possible mechanism for the ataxic symptoms in these patients ([@bib136]). In addition, BK channel inhibitors produce ataxia when ingested or injected ([@bib69]; [@bib99]; [@bib63]; [@bib74]), supporting association between BK channel LOF and ataxic movement disorder.

Baseline axial hypotonia is another motor dysfunction symptom most prominent with LOF mutations ([Fig. 4](#fig4){ref-type="fig"}). The axial hypotonia reported in 8 of 13 LOF patients ranged from mild to severe and was independent from PNKD-associated symptoms noted in GOF patients ([@bib158];[@bib89]). Additionally, tremor was noted in two LOF patients, and is a phenotype shared with BK channel KO mice ([@bib136]; [@bib69]), but specific details describing this symptom were not provided ([@bib197]; [@bib89]). Further diagnostic studies are required to determine if these movement disorder attacks are due to mutant BK channel activity within the affected muscle groups, or whether they are secondary to CNS dysfunction, as both mechanisms are seen in a variety of channelopathies associated with movement disorders ([@bib46]).

Seizure disorder {#s11}
----------------

Seizure is another predominant symptom associated with both GOF and LOF *KCNMA1* mutations. 18 of the 37 patients described in this review developed epileptic seizures. However, there was considerable variability among the characteristics of the seizures such as age of onset, type, EEG pattern, frequency and duration, and response to medications. None of these characteristics are clearly delineated by the mutation type. Both GOF and LOF mutations are associated with overlapping seizure phenotypes including myoclonic ([@bib158]; [@bib87]), generalized tonic-clonic (GTCS; [@bib28]; [@bib158]; [@bib197]), and absence seizures ([@bib28]; [@bib87]; [@bib197]; [@bib89]; [Fig. 4](#fig4){ref-type="fig"}). Interestingly, all nine GOF patients experienced absence seizures whereas only three of six LOF patients experienced them. Atonic seizures and status epilepticus were only reported in two different patients expressing LOF mutations ([@bib197]; [@bib89]). 10 of the 18 patients were reported to have abnormal inter-ictal EEG findings ranging from mild background slowing to generalized spike wave complexes to Lennox-Gastaut patterning ([@bib28]; [@bib158]; [@bib87]; [@bib197]). Age of onset for seizure also varied between patients regardless of the mutation type. Of the 13 family members expressing a D434G GOF mutation, 6 were diagnosed with epilepsy at ages ranging from 6 mo and 9 yr ([@bib28]). Three of the seven patients expressing a N995S or N999S GOF mutation began experiencing seizures at 20 mo, 6 yr, and 9 yr of age ([@bib87]; [@bib56]; A.L. Meredith and S. Keros, personal observations), and the two siblings with the same Y676Lfs\*7 putative LOF mutation had seizures beginning at one year of age ([@bib158]). As in the general population, it is likely that seizure heterogeneity with this subset of patients is heavily influenced by additional factors ([@bib155]).

Neurodevelopmental and cognitive phenotypes {#s12}
-------------------------------------------

Patients with both GOF and LOF *KCNMA1* alleles showed developmental delay and intellectual disability ([Fig. 4](#fig4){ref-type="fig"}). Of the 37 patients reported in the literature, 21 were described as having developmental delay ([@bib203]; [@bib15]; [@bib180]; [@bib87]; [@bib197]; [@bib56]; [@bib89]) and 12 were noted to have intellectual disability ([@bib203]; [@bib15]; [@bib180]; [@bib56]; [@bib89]). The developmental delays ranged from mild to severe and included psychomotor symptoms such as delayed/unstable sitting, inability to support head or walk unassisted, speech delay, and global developmental delay ([@bib203]; [@bib158]; [@bib56]; [@bib89]). A subset of neurodevelopmental symptoms has only been described in patients with LOF *KCNMA1* alleles ([Fig. 4](#fig4){ref-type="fig"}). One patient had hearing impairment ([@bib89]), and multiple patients demonstrated visual impairment due to nystagmus, strabismus, and macular coloboma ([@bib15]; [@bib89]). Two patients had autism disorder or features ([@bib56]; A.L. Meredith and S. Keros, personal observations), which together with mental retardation was previously associated with a potential LOF SNP in *KCNMA1* ([@bib84]).

Lessons from animal studies linking changes in BK channel function to neurological phenotypes {#s13}
---------------------------------------------------------------------------------------------

Within the rodent brain, high levels of BK channel expression are detected in the neocortex, basal ganglia, hippocampus, thalamus, habenula and its tract to the interpeduncular nucleus in the midbrain, cerebellum, vestibular nuclei in the hindbrain, and olfactory system ([@bib77]; [@bib182]; [@bib108]; [@bib140]; [@bib200]). Animals with functional deficiency of BK channels displayed behaviors that can recapitulate some of the movement symptoms in patients with putative LOF *KCNMA1* mutations. Pharmacological inhibition of BK channels with lolitrem B or paxilline induced tremor and ataxia in mice and livestock ([@bib69]), and constitutive deletion of *KCNMA1* (*KCNMA1^−/−^*) produced several types of motor impairments such as ataxia, tremor, impaired motor coordination, reduced muscle strength, and abnormal eye blink reflex in mice ([@bib106]; [@bib136]; [@bib69]; [@bib168]). The motor impairments exhibited by *KCNMA1^−/−^* mice suggested cerebellar dysfunction. Consistent with this, *KCNMA1^−/−^* Purkinje neurons showed significantly reduced basal firing activity and increased short term transmission depression at synapses on deep cerebellar nuclei and disrupted olivo-cerebellar feedback ([@bib136]; [@bib16]). The direct influence of GOF mutations in BK channel function on motor control has not yet been investigated, but mice harboring a strong (nonpatient-derived) GOF mutation that increases voltage-dependent gating of the BK channel (R207Q) have grossly normal locomotor behavior ([@bib109]). Taken together, the results from animal models demonstrate that BK channel LOF is associated with movement disorder phenotypes that are also observed in human patients, and further suggest the potential for segregation of distinct motor dysfunction with LOF versus GOF BK channel alterations.

Unlike motor dysfunction, both LOF and GOF alterations in BK channel activity have been linked with the seizure pathophysiology in animal studies. In a chronic temporal lobe epileptic rat model, expression of the BK channel α-subunit encoded by *KCNMA1* was down-regulated in hippocampus and cortex ([@bib31]; [@bib121]), suggesting a link between seizure and LOF in BK channel activity. BK channel expression and BK current levels were also reduced in the inferior colliculus during alcohol withdrawal periods in a rat model of alcohol withdrawal seizures ([@bib112]). However, a direct causal relationship between LOF alterations in BK channel activity and epileptogenesis has not yet been reported.

There is a more solid correlation between GOF alterations in BK channel activity and seizure. Deletion of regulatory β4 subunit (*KCNMB4^−/−^*), which slows BK channel activation, produced temporal lobe seizures cortex in mice, associated with hyperactive firing in dentate granule (DG) cells in the hippocampus ([@bib13]). In addition, kainic acid--induced seizure susceptibility was increased in β4 heterozygous mice ([@bib186]). Furthermore, in a model of fragile X syndrome, enhancement of BK channel activity in *KCNMB4^−/−^* mice was associated with alterations in epileptiform activity in hippocampal slices ([@bib25]). Several other studies also show situations where increased BK channel expression was associated with hyperexcitability and seizure activity. Elevated cell surface expression and activity of BK channels via mutation of CRL4A^CRBN^ ubiquitin ligase increased susceptibility to spontaneous and PTZ-induced seizures in mice, an effect that can be reduced by pretreatment of the mice with the BK channel inhibitor paxilline ([@bib90]). Up-regulation of BK α and down-regulation of β4 protein were reported after seizure induction in rats ([@bib142]), and β4 mRNA was down-regulated in DG cells in the hippocampus following pilocarpine-induced seizure ([@bib186]). BK currents in somatosensory cortex were significantly increased after picrotoxin-induced seizure in mice, and the increased neuronal firing activity was normalized with BK channel inhibitors ([@bib146]). Similarly, BK blockers normalized DG cell firing rates that were increased during pilocarpine-induced seizure episodes in rats ([@bib102], [@bib103]). These animal studies show that GOF alterations in BK channel activity, either via increased expression or due to loss of the slow gating imparted by the β4 subunit, alters the balance of neuronal activity in the brain. GOF *KCNMA1* mutations affecting BK channel activity in mechanistically similar ways could be causative in *KCNMA1*-linked patient seizures.

Inheritance and prevalence of *KCNMA1*-linked channelopathy {#s14}
-----------------------------------------------------------

The majority of the pathogenic *KCNMA1* mutations reported in the literature occurred de novo, however few mutations exhibit autosomal recessive or autosomal dominant inheritance patterns ([Fig. 1](#fig1){ref-type="fig"}). To date, the literature reports a total of 16 mutations identified in 37 symptomatic patients ([@bib28]; [@bib203]; [@bib15]; [@bib158]; [@bib180]; [@bib87]; [@bib197]; [@bib56]; [@bib89]). 17 patients have de novo mutations, which constitute 9/16 *KCNMA1* mutations. 4 patients inherited an autosomal recessive mutation, constituting 3/16 mutations. 13 patients (one family) inherited a single (1/16) autosomal dominant mutation. Additionally, there are three benign *KCNMA1* genetic variants (3/16) identified in three patients with epilepsy ([@bib87]). One of these three variants exhibited an autosomal recessive inheritance pattern, but the inheritance patterns for the other two variants were not determined.

*KCNMA1*-linked channelopathy is a very rare syndrome. The allele frequency of certain pathogenic *KCNMA1* mutations in larger populations is estimated to be less than 1:100,000 in the Genome Aggregation Database (D434G = 3 × 10^−5^ and Y676Lfs\*7 = 4 × 10^−6^; [@bib86]). However, the allele frequency in larger populations is unknown for majority of the pathogenic *KCNMA1* mutations owing to the rarity of this syndrome. Table S1 provides information regarding the number of missense SNPs present in *KCNMA1* and putative pathogenic mutations reported by different large-scale sequencing databases.

Diagnosis and treatment of *KCNMA1*-linked channelopathy {#s15}
--------------------------------------------------------

Epilepsy and movement disorders are known to be caused by several different medical conditions, a subset of which are the result of monogenetic channelopathies ([@bib11]; [@bib76]). Traditionally, if a patient presents with epileptic seizures and movement attacks with otherwise unremarkable brain imaging and normal neurological function between episodes, then a genetic channelopathy is a leading consideration and genetic testing is recommended to search for causative genetic mutations. The D434G mutation was initially mapped via microsatellite linkage analysis ([@bib28]); however, causative genetic findings in neurological disorders are more routinely established now by single gene analysis, panels of multiple gene tests for disorders which share a specific phenotype, or by high-powered WES or whole genome sequencing (WGS; [@bib128]). When patient symptoms are extensive and a test for multiple pathogenic genetic mutations is desired, WES is typically used instead of WGS ([@bib78]). WES is less costly than WGS, and the majority of pathogenic variants are found within the coding regions or splice sites of proteins. However, WES is prone to incomplete coverage of certain loci, variability in coverage from person to person, and has susceptibility to false positives and negatives. Of the 37 patients described in the literature, 21 were identified to have a *KCNMA1* mutation using WES ([@bib153]; [@bib158]; [@bib87]; [@bib197]; [@bib56]; [@bib89]).

On the other hand, when the clinical symptoms are well defined or stereotypical such as generalized epilepsy and paroxysmal dyskinesia, as is the case with some patients with *KCNMA1*-linked channelopathy, a limited set of specific candidate genes are assayed. At present, 29 commercial gene panels include *KCNMA1* (Table S2). Of note, the genes included with each panel are frequently updated as additional genetic mutations are associated with specific medical conditions. Three of the 37 patients with *KCNMA1* mutations were identified using epilepsy- and paroxysmal dyskinesia--specific gene panels ([@bib203];[@bib180]).

Development of treatment regimens specific for *KCNMA1*-linked channelopathy ("precision medicine") is currently limited by several important factors, including (a) lack of FDA-approved selective BK channel pharmacological modulators, (b) lack of stereotypical clinical presentations with respect to core symptoms (movement disorder and seizure), (c) lack of established causality between alterations in channel activity and patient symptoms, and (d) inadequate medical assessment identifying the loci for symptoms in patients. Thus, the majority *KCNMA1*-linked channelopathy patients with seizures have been treated with anti-seizure medications (ASMs) selected with the same general approach as for any nonsyndromic epilepsy. Several *KCNMA1* patient studies commented on the efficacy of various ASMs and demonstrate the range of patient responses may range from positive, to no response, to negative.

Sodium valproate and/or lamotrigine were effective in treating the absence seizures in the proband with the GOF D434G mutation ([@bib28]), as well as the absence, GTCS, and atonic seizures in a patient with the LOF R458Ter\* mutation ([@bib197]), and myoclonic seizures in a patient with homozygous LOF Tyr676Leufs\*7 mutation ([@bib158]). These two ASMs were also used to treat absence seizures in two patients with the LOF G375R mutation, but efficacy of the treatments was not reported ([@bib89]). The second patient with the homozygous Tyr676Leufs\*7 mutation and myoclonic seizures and GTCS was treated effectively with sodium valproate and levetiracetam ([@bib158]). Levetiracetam alone was effective to treat atypical absence and myoclonic seizures in two patients with the GOF N995S mutation ([@bib87]). However, one of these patients was trialed on various ASMs before levetiracetam; treatment with oxcarbazepine, and sodium valproate produced negative side effects, sultiame and perampanel did not have any effects, and zonisamide monotherapy reduced the seizure frequency, but failed to stop the myoclonic seizures. Notably, this patient experienced significant worsening of seizures with ethosuxmide, the drug of choice for the absence seizures seen in childhood absence epilepsy. A dramatic worsening of absence seizures at very low doses of ethosuximide also occurred in a GOF N999S patient, reported in [@bib56], while levetiracetam was not tolerated due to side effects (S. Keros, personal observation). The patient with a LOF D984N mutation was diagnosed with status epilepticus and treated with several ASMs including clobazam, ethosuximide, lamotrigine, zonisamide, sodium valproate, phenobarbital, and lacosamide, but the therapeutic efficacy was not known ([@bib89]).

Paroxysmal dyskinesias are commonly categorized into three main types (kinesigenic or paroxysmal kinesigenic dyskinesia, nonkinesigenic or PNKD, and exercise-induced or PED), and each type has been shown to respond differently to medications ([@bib171]). PNKD, the dominant type associated with *KCNMA1*-linked channelopathy, is commonly described as refractory to medications. However, benzodiazepines, particularly clonazepam, and some ASMs have been shown to be effective in some PNKD patients ([@bib171]). Additional therapies used to treat other movement disorders, such as acetazolamide in episodic ataxia, have demonstrated positive effects in some patients with PNKD ([@bib147]). Acetazolamide is a carbonic anhydrase inhibitor and has been suggested as a possible direct agonist of BK channels in rat cerebellar neurons and skeletal muscle ([@bib167]; [@bib2]; [@bib166]). However, the potentiating mechanism for acetazolamide on either WT or mutant BK channels is not currently well established.

There are a limited number of reports assessing PNKD treatment and related symptoms in patients harboring *KCNMA1* mutations. Clonazepam was partially effective for two patients with GOF D434G mutations ([@bib28]) and reduced the frequency of PNKD attacks in one patient with the N1053S mutation ([@bib180]). Clonazepam was also used to treat dyskinetic tremor, dystonia, and spasticity of the lower extremities in a patient with the R458Ter\* mutation ([@bib197]). A second patient with the GOF N1053S mutation and paroxysmal dystonic postures was unresponsive to oxcarbazepine, sodium valproate, and levetiracetam ([@bib203]), whereas a patient with the GOF N999S mutation experiencing paroxysmal drop attacks responded positively to DHA and acetazolamide after not responding to clonazepam, amitriptyline, or levetiracetam ([@bib56]). A second patient with the N999S mutation and experiencing the paroxysmal drop attacks did not respond to levetiracetam, carbamazepine, valproic acid, vitamin B complex, CBD oil, DHA, 5-HIAA, or pimozide ([@bib56]; A.L. Meredith and S. Keros, personal observations). Overall, within the *KCNMA1*-linked channelopathy population, patient responses to therapies treating seizure and movement disorders are not predictable a priori.

Precision medicine and future directions {#s16}
----------------------------------------

For most genetic channelopathies, pharmacologic treatment does not yet consist of modulating the specific activity of mutant ion channels. For *KCNMA1* and other channelopathies, the first hurdle to precision medicine involves categorizing patient mutations into functional classes, such as GOF or LOF. However, these classes are not trivial to define and can be condition- or cell-type specific, related to the particular splice variants, accessory subunits, post-translational channel modifications, and cellular contexts (intracellular calcium, in particular for the BK channel) in which the mutation is tested. For this reason, it is not yet clear whether strategies using patient-derived stem cells, which can only be differentiated into a limited set of cell types, would result in BK channel pharmacological modulators that are ultimately clinically relevant. In addition, GOF, LOF, and potentially benign mutations in BK channel activity are associated with overlapping symptoms ([Fig. 4](#fig4){ref-type="fig"}), raising the question of whether selective agonists or antagonists that restore the "correct" level of BK channel activity will actually produce the desired outcome on neuronal activity. Without more detailed information about the origination of the changes in excitability underlying the seizure and movement symptoms in *KCNMA1*-linked channelopathy, it is difficult to ascertain which BK channel components to target, and in which neuron or muscle loci.

Selective BK channel pharmacotherapy has been under development for over two decades, mostly intended to treat smooth muscle dysfunction resulting from LOF in BK channel activity (hypertension, bladder incontinence, stroke, and erectile dysfunction; [@bib17]; [@bib47]; [@bib151]; [@bib173]; [@bib148]; [@bib91]). Several compounds, including endogenous, naturally occurring, and synthetic, have been identified as BK agonists and trialed as potential therapeutic agents ([@bib66]; [@bib8]; [@bib63]). The endogenous class includes heme and heme-breakdown products ([@bib159]; [@bib62]), free long-chain polyunsaturated acids ([@bib19], [@bib20]), metabolites of cytochrome P450, epoxygenase and lipoxygenase ([@bib38]; [@bib66]), and 17 β-estradiol ([@bib172]). The natural occurring class includes a variety of entities found in herbs, roots, and leaves used in folk medicines for treating asthma and other disorders stemming from smooth muscle dysfunction such as DHS-I ([@bib100]; [@bib115]). The synthetic class includes benzimidazolone compounds NS004 and NS1619 ([@bib118],[@bib119]), the more potent and selective NS11021 ([@bib7]), and a newer family of BK channel activators called the GoSlo-SR family (anthra-quinone analogues; [@bib135]). At least one compound, Cym04 (a dehydroabietic acid derivative) has been shown to demonstrate some specificity for a particular BK channel splice variant ([@bib23]; [@bib40]). Despite the ability of these chemical agents to activate BK channels in vitro and animal studies, only a single drug with therapeutic action targeting the BK channel is FDA approved ([@bib24]). This drug, Rescula (unoprostone isopropyl ophthalmical solution) is a potent BK channel activator used to reduce ocular pressure in glaucoma ([@bib162]).

Other potential, but nonselective, neuromodulators that may affect BK channels include docosahexaenoic acid (DHA), an omega-3 fatty acid found in oily fish, acetazolamide, zonisamide, and riluzole. DHA reversibly binds BKα/β1 expressed primarily in smooth muscle and BKα/β4 channels expressed primarily in the nervous system in mice. DHA increases peak BK current by 20- to 30-fold at certain physiological voltages ([@bib64]), suggesting potential efficacy for enhancing LOF BK channel activity. While DHA injection in mice lowers blood pressure ([@bib65]), the physiological roles of this fatty acid within the nervous system are not well defined. Injection of DHA in rats increased latency of PTZ-induced seizure implicating its neuroprotective effect (([@bib165])); however, a systemic review assessing protective role of omega-3 supplementation in human seizures reported inconclusive evidence of benefit ([@bib127]). Two patients with *KCNMA1*-linked channelopathy have been trialed on DHA (in combination with acetazolamide; [@bib56]). However, the patients harbor a mutation classified as GOF, suggesting any potential therapeutic effect conferred by DHA might not originate from direct modulation of the BK channel. Thus, the data provide no specific indication on the therapeutic potential for DHA in *KCNMA1*-linked channelopathy patients. Similarly, although acetazolamide has been reported to have agonist effects on BK channels in skeletal muscle ([@bib167]; [@bib27]), this has not yet been substantiated on BK channels expressed in heterologous cells or neurons. Two other neurological drugs, zonisamide (an ASM) and riluzole, increased K^+^ currents in hippocampal and skeletal cell lines respectively, an effect that was blocked by BK channel inhibitors ([@bib68]; [@bib181]).

Another potential pharmacotherapy based on FDA-approved drugs to normalize BK channel activity associated with GOF mutations is Ca^2+^ channel inhibitors. For GOF mutations, decreasing the Ca^2+^-dependent activation could reduce BK current. While this approach could require knowledge of the specific Ca^2+^ source for the channels in tissues where excitability is altered in the patients, one class of inhibitors, dihydropyridines (DHPs), are known to inhibit BK channel activation in a variety of central neurons ([@bib36]; [@bib201]; [@bib179]; [@bib188]). The DHPs, nifedipine and nimodipine, and the non-DHP verapamil, are used for some types of dyskinesia ([@bib1]). Verapamil has been used for refractory epilepsy and hyperkinetic movement disorders ([@bib120]; [@bib114]; [@bib81]). In addition, there is at least one report that Verapamil might block BK channels directly, further contributing to a reduction in channel activity through a selective mechanism ([@bib53]). However, it has not yet been investigated whether doses effective at reducing BK channel activity in the brain would have cardiac side effects.

Beyond pharmacology, some therapeutic approaches tailored for individual patients with other monogenetic disorders may be conceivable in the future for *KCNMA1*-linked channelopathy, such as gene editing, gene therapy, or optogenetic restoration of neuronal activity. Yet, substantial challenges are present for their application to any disease or disorder, including target specificity, delivery optimization, elimination of off-target side effects, timing optimization before or after critical stages of neurological development ([@bib190]), and creating animal models that best replicate the genetic channelopathy from the molecular level to the clinical phenotype to determine initial safety and efficacy of such therapies ([@bib161]). While these precision medicines may hold eventual promise, until the challenges are overcome, development of additional pharmacological approaches remains the major path forward clinically.
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